Edition:
United Kingdom

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

4.74USD
18 Jan 2019
Change (% chg)

$-0.01 (-0.21%)
Prev Close
$4.75
Open
$4.71
Day's High
$4.87
Day's Low
$4.53
Volume
158,187
Avg. Vol
92,741
52-wk High
$12.35
52-wk Low
$4.51

Latest Key Developments (Source: Significant Developments)

Zafgen Expects To Present Phase 2 Study Results For Zgn-1061 At Upcoming Medical Meeting
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Zafgen Inc ::ZAFGEN ANNOUNCES POSITIVE RESULTS FOR SECOND COHORT OF PHASE 2 CLINICAL TRIAL OF ZGN-1061.ZAFGEN INC - IN STUDY, DATA FOR 1.8 MG DOSE DEMONSTRATED MEANINGFULLY GREATER EFFICACY THAN 0.9 MG DOSE.ZAFGEN INC - COHORT 2 DATA SHOWED STATISTICALLY AND CLINICALLY SIGNIFICANT 1.1% REDUCTION OF A1C AT 1.8 MG DOSE RELATIVE TO PLACEBO.ZAFGEN INC - STUDY RESULTS CONTINUE TO SUPPORT FAVORABLE SAFETY AND TOLERABILITY PROFILE OF ZGN-1061.ZAFGEN INC - IN STUDY, ZGN-1061 WAS GENERALLY SAFE AND WELL-TOLERATED, WITH AN ADVERSE EVENT (AE) PROFILE COMPARABLE TO PLACEBO.ZAFGEN - EXPECTS TO PRESENT FULL RESULTS OF PHASE 2 CLINICAL TRIAL FOR ZGN-1061, INCLUDING 1.8 MG DOSE COHORT, AT AN UPCOMING MEDICAL MEETING IN 2019.  Full Article

Zafgen Inc Files For Mixed Shelf Of Up To $200 Million
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Zafgen Inc ::ZAFGEN INC FILES FOR MIXED SHELF OF UP TO $200 MILLION – SEC FILING.  Full Article

Zafgen Announces Proposed Offering Of Common Stock
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Zafgen Inc ::ZAFGEN ANNOUNCES PROPOSED OFFERING OF COMMON STOCK.  Full Article

Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN SAYS ‍ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT​ OF $20 MILLION - SEC FILING.  Full Article

Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Zafgen Inc ::ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018.ZAFGEN- INCREASED CASH POSITION DURING Q4, EXPECTS TO END CALENDAR YEAR 2017 WITH OVER $100 MILLION IN CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES.ZAFGEN INC - WELL-CAPITALIZED TO SUPPORT ITS CLINICAL-STAGE DEVELOPMENT PROGRAMS BEYOND FIRST HALF OF 2019.ZAFGEN - ‍ENTERED A $20 MILLION VENTURE DEBT FINANCING AGREEMENT WITH SILICON VALLEY BANK ON DEC 29, EXTENDING EXPECTED CASH RUNWAY BEYOND H1 2019​.ZAFGEN INC - TOPLINE DATA ARE EXPECTED IN MID-YEAR 2018 FOR ZGN-1258.ZAFGEN -FOR ZGN-1258,‍ BEGINNING IND APPLICATION-ENABLING WORK IN Q1 FOR FILING WITH U.S. FDA, BEGINNING PHASE 1 CLINICAL DEVELOPMENT BY END OF YEAR​.  Full Article

Zafgen reports Q3 loss per share $0.46
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Zafgen Inc :Zafgen reports third quarter 2017 financial results.Q3 loss per share $0.46.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Zafgen- continues to expect its cash, cash equivalents and marketable securities balance to be greater than $70 million as of december 31, 2017​.Zafgen Inc - ‍initiated phase 2 clinical trial for second generation metap2 inhibitor ZGN-1061​.  Full Article

Zafgen appoints Jeffrey Hatfield as CEO
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Zafgen Inc ::Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer.Zafgen Inc - Hatfield and Hughes will serve on Zafgen's board of directors​.  Full Article

US STOCKS-Wall Street rallies as Cyber Monday shoppers log on

* Indexes up: Dow 1.46 pct, S&P 1.55 pct, Nasdaq 2.06 pct (Updates to market close)